Distinct Early Folding and Aggregation Properties of Alzheimer Amyloid-beta Peptides Abeta40 and Abeta42: Stable Trimer or Tetramer Formation by Abeta42
Overview
Authors
Affiliations
The amyloid beta peptide (Abeta), composed of 40 or 42 amino acids, is a critical component in the etiology of the neurodegenerative Alzheimer disease. Abeta is prone to aggregate and forms amyloid fibrils progressively both in vitro and in vivo. To understand the process of amyloidogenesis, it is pivotal to examine the initial stages of the folding process. We examined the equilibrium folding properties, assembly states, and stabilities of the early folding stages of Abeta40 and Abeta42 prior to fibril formation. We found that Abeta40 and Abeta42 have different conformations and assembly states upon refolding from their unfolded ensembles. Abeta40 is predominantly an unstable and collapsed monomeric species, whereas Abeta42 populates a stable structured trimeric or tetrameric species at concentrations above approximately 12.5 microm. Thermodynamic analysis showed that the free energies of Abeta40 monomer and Abeta42 trimer/tetramer are approximately 1.1 and approximately 15/ approximately 22 kcal/mol, respectively. The early aggregation stages of Abeta40 and Abeta42 contain different solvent-exposed hydrophobic surfaces that are located at the sequences flanking its protease-resistant segment. The amyloidogenic folded structure of Abeta is important for the formation of spherical beta oligomeric species. However, beta oligomers are not an obligatory intermediate in the process of fibril formation because oligomerization is inhibited at concentrations of urea that have no effect on fibril formation. The distinct initial folding properties of Abeta40 and Abeta42 may play an important role in the higher aggregation potential and pathological significance of Abeta42.
Chen G, Chang M, Lin X, Kundu D, Chang Y, Chen Y J Biol Chem. 2025; 301(2):108184.
PMID: 39814228 PMC: 11849630. DOI: 10.1016/j.jbc.2025.108184.
Aducanumab-Hope or Disappointment for Alzheimer's Disease.
Wojtunik-Kulesza K, Rudkowska M, Orzel-Sajdlowska A Int J Mol Sci. 2023; 24(5).
PMID: 36901797 PMC: 10002282. DOI: 10.3390/ijms24054367.
Signal peptide stabilizes folding and inhibits misfolding of serum amyloid A.
Wu J, Chen Y Protein Sci. 2022; 31(12):e4485.
PMID: 36309973 PMC: 9667897. DOI: 10.1002/pro.4485.
Based on molecular structures: Amyloid-β generation, clearance, toxicity and therapeutic strategies.
Yang H, Li J, Li X, Ma L, Hou M, Zhou H Front Mol Neurosci. 2022; 15:927530.
PMID: 36117918 PMC: 9470852. DOI: 10.3389/fnmol.2022.927530.
Xie J, Gorle N, Vandendriessche C, Van Imschoot G, Van Wonterghem E, Van Cauwenberghe C Acta Neuropathol Commun. 2021; 9(1):163.
PMID: 34620254 PMC: 8499584. DOI: 10.1186/s40478-021-01253-z.